Tag Archives: Oral

ADA: Novo Nordisk’s oral semaglutide posts another heart safety win

SAN FRANCISCO—Novo Nordisk may have already submitted its approval application for its oral GLP-1 drug semaglutide, but the deluge of positive data hasn’t stopped. Tuesday at the American Diabetes Association annual meeting, the Danish drugmaker rolled out cardiovascular outcomes results showing that the its wannabe blockbuster didn’t hurt cardiovascular safety in high-risk Type 2 diabetes… Read More »

Omadacyline Now Available in IV, Oral Forms for CABP, ABSSSI

February 08, 2019 This article originally appeared here. Share this content: Paratek also announced the availability of 3 FDA-approved antimicrobial susceptibility tests. Paratek announced the launch of Nuzyra (omadacycline) for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). It is the first once-daily antibiotic approved to… Read More »